Literature DB >> 104804

Quantitative determination of trinitroglycerin in human plasma.

J Y Wei, P R Reid.   

Abstract

We developed a simplified method for quantitative measurement of trinitroglycerin in human plasma using hexane extraction and analysis by gas-liquid chromatography with electron-capture detection. This assay was linear from 0.5-60 ng/ml. Sensitivity and reproducibility were +/- 0.5 ng/ml. We used this assay to evaluate the pharmacodynamics of trinitroglycerin in 14 patients. Maximum plasma levels were similar with trinitroglycerin given by constant intravenous infusion (1.6 +/- 0.4 ng/ml (SEM)), transcutaneously (2.3 +/- 0.6 ng/ml), or sublingually (1.6 +/- 0.6 ng/ml). Despite similar levels and hemodynamic responses after intravenous trinitroglycerin, the dose range was wide (37.5-175 microg/min, n = 5), emphasizing the need to individualize therapy. In normal volunteers on no other drugs, the plasma level time course followed changes in heart rate better than blood pressure changes. Use of the trinitroglycerin assay may enhance optimization of trinitroglycerin therapy when administered by different methods.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 104804     DOI: 10.1161/01.cir.59.3.588

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Influence of posture on plasma nitroglycerin.

Authors:  S H Curry; H R Kwon
Journal:  Br J Clin Pharmacol       Date:  1985-03       Impact factor: 4.335

3.  The effect of glyceryl trinitrate ointment on heart rate--corrected systolic time intervals in angina pectoris.

Authors:  A D Struthers; B Whiting; W S Hillis; A W Kelman
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

4.  Plasma concentrations and haemodynamic effects of nitroglycerin during and after intravenous infusion in healthy volunteers.

Authors:  P R Imhof; A Sieber; J Hodler; P Müller; B Ott; P Fankhauser; L C Chu; A Gérardin
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

6.  Pharmacological interaction between nitroglycerin and aspirin after acute and chronic aspirin treatment of healthy subjects.

Authors:  E Rey; H D El-Assaf; M O Richard; S Weber; A Bourdon; G Picard; G Olive
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

8.  Inhibitory effects of glyceryl trinitrate on alpha-adrenoceptor mediated contraction in the human internal mammary artery.

Authors:  G W He; J Shaw; C Q Yang; C Hughes; D Thomson; B McCaughan; P N Hendle; D K Baird
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

9.  Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure.

Authors:  P W Armstrong; D G Watts; J A Moffat
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.